tradingkey.logo
tradingkey.logo
Search

ARS Pharmaceuticals Inc

SPRY
Add to Watchlist
8.560USD
+0.620+7.81%
Close 07/02, 13:00ETQuotes delayed by 15 min
850.01MMarket Cap
LossP/E TTM

More Details of ARS Pharmaceuticals Inc Company

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

ARS Pharmaceuticals Inc Info

Ticker SymbolSPRY
Company nameARS Pharmaceuticals Inc
IPO dateDec 04, 2020
CEOLowenthal (Richard E)
Number of employees155
Security typeOrdinary Share
Fiscal year-endDec 04
Address11682 El Camino Real, Suite 300
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone18587719307
Websitehttps://ars-pharma.com/
Ticker SymbolSPRY
IPO dateDec 04, 2020
CEOLowenthal (Richard E)

Company Executives of ARS Pharmaceuticals Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
10.06M
+32.09%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
1.25M
-266.69%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
82.90K
-4.05%
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Saqib Islam, J.D.
Mr. Saqib Islam, J.D.
Independent Director
Independent Director
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric Karas
Mr. Eric Karas
Chief Commercial Officer
Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
10.06M
+32.09%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
1.25M
-266.69%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
82.90K
-4.05%
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--

FAQs

Who are the top five shareholders of ARS Pharmaceuticals Inc?

The top five shareholders of ARS Pharmaceuticals Inc are: Mr. Richard E. Lowenthal

How many institutions hold shares of ARS Pharmaceuticals Inc (SPRY)?

As of 2026Q1, 412 institutions hold shares of ARS Pharmaceuticals Inc, with a combined market value of approximately 96.79M, accounting for 97.47% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -8902286.00.